Descripción de la empresa
Foghorn Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery and development of therapeutic medicines that target genetically determined dependencies within the chromatin regulatory system in the United States. The company leverages its proprietary Gene Traffic Control platform to identify and develop novel treatments, positioning itself within the broader Healthcare sector and the specialized Biotechnology industry. As of the latest available data, the enterprise holds a market capitalization of $291.74 million and employs a workforce of 106 individuals, generating annual revenue totaling $30.91 million. These financial figures indicate that the company operates as a mid-cap biotechnology firm with a relatively small revenue base compared to its market valuation, a structural characteristic common in clinical-stage development companies that prioritize R&D investment over immediate profitability.
Salud financiera
The company reported a trailing twelve-month revenue of $30.91 million, yet it recorded a net loss of $-74,283,000 and an EBITDA of $-78,775,000 during the same period. The substantial negative gap between revenue and net income reveals a cost structure heavily burdened by research and development expenses that far exceed the current revenue generation capabilities. Free cash flow stands at $-35,229,876, indicating that the company is currently consuming cash reserves to fund its operations and development pipeline rather than generating liquidity from its core business. This negative cash flow position necessitates careful capital management, as the company must rely on existing cash reserves or external financing to sustain its financial flexibility. The company reports a gross margin of -176.5%, an operating margin of -211.9%, and a profit margin of -240.3%, all of which are negative and reflect the pre-revenue or low-revenue reality typical of early-stage biotechnology ventures where costs are incurred without proportional sales. In terms of leverage, the company holds $158.89 million in cash against $41.27 million in debt, while the debt-to-equity ratio is listed as N/A due to equity constraints or accounting treatments common in loss-making firms. Despite the lack of a traditional debt-to-equity metric, the net cash position suggests a conservative balance sheet regarding solvency, provided the cash can be deployed effectively. The current ratio is 2.73, which indicates a strong ability to meet short-term obligations with its current assets relative to current liabilities. Return on Equity is listed as N/A, while Return on Assets is -21.3%, metrics that collectively reveal that management is currently generating negative returns on the capital base employed, a standard characteristic for companies investing heavily in future product potential rather than current shareholder yield.
Evaluación de valoración
The trailing P/E ratio is N/A because the company is not currently profitable, while the forward P/E is reported as -5.45, a metric that implies the market is pricing in future earnings that do not yet exist or are expected to be negative in the immediate forward period. The price-to-book ratio is -2.60, indicating that the market values the company at a negative multiple of its book value, a situation often seen in biotech firms where intangible assets and pipeline value are not fully captured on the balance sheet. The price-to-sales ratio stands at 9.44, suggesting that the market is valuing the company at a premium relative to its current sales, which reflects high expectations regarding the potential success of its drug pipeline. Additionally, the EV/EBITDA multiple is -2.21, an alternative valuation metric that further highlights the disconnect between current earnings power and market price due to significant operating losses. Regarding trading ranges, the 52-week high is $6.95 and the 52-week low is $3.00, meaning the current trading price sits within this volatility band but below the recent peak, reflecting the speculative nature of the stock. The beta value is 3.11, which signifies that the stock exhibits high price volatility and tends to move significantly more aggressively than the broader market, amplifying both potential gains and losses during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year is an impressive 223.8%, driven likely by the recognition of milestones, licensing agreements, or initial sales of early-stage products, whereas earnings growth is N/A due to the persistent net losses. The divergence between revenue expansion and the absence of earnings growth implies that while the top line is scaling rapidly, the bottom line remains constrained by the high fixed costs of clinical development. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that it retains all earnings to reinvest into research and development rather than distributing cash to shareholders. This reinvestment strategy is consistent with the biotechnology business model, where capital allocation focuses on advancing clinical trials and securing regulatory approval rather than providing current income. The overall growth and income profile is defined by rapid top-line expansion coupled with significant cash burn and a complete lack of current profitability or dividend distribution.